title: Discontinuation of growth hormone (GH) treatment during the transition phase is an important factor determining the phenotype of young adults with nonidiopathic childhood-onset GH deficiency.
authors.affiliation: KIGS/KIMS Medical Outcomes, Pfizer Health AB, Endocrine Care, SE-190 91 Sollentuna, Sweden. maria.koltowska-haggstrom@pfizer.com
authors.forename: Maria
authors.initials: M
authors.lastname: Kołtowska-Häggström
authors.forename: Mitchell E
authors.initials: ME
authors.lastname: Geffner
authors.forename: Peter
authors.initials: P
authors.lastname: Jönsson
authors.forename: John P
authors.initials: JP
authors.lastname: Monson
authors.forename: Roger
authors.initials: R
authors.lastname: Abs
authors.forename: Václav
authors.initials: V
authors.lastname: Hána
authors.forename: Charlotte
authors.initials: C
authors.lastname: Höybye
authors.forename: Hartmut A
authors.initials: HA
authors.lastname: Wollmann